Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 6, 2007, Pages

  Durst, Ronen ^a,c   Danenberg, Haim ^a   Gallily, Ruth ^a   Mechoulam, Raphael ^a   Meir, Keren ^b   Grad, Etty ^a   Beeri, Ronen ^a   Pugatsch, Thea ^a   Tarsish, Elizabet ^a   Lotan, Chaim ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cannabinoids; Ischemia reperfusion; Myocardial infarction; Pharmacotherapy

Indexed keywords

CANNABIDIOL; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CANNABIDIOL; CANNABIS; CARDIOVASCULAR AGENTS; CORONARY CIRCULATION; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; GRANULATION TISSUE; INTERLEUKIN-6; LIGATION; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR PRESSURE;

EID: 36849091565     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00098.2007     Document Type: Article

References (38)

1. 1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134: 845-852, 2001.
2. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 45: 50-52, 2006.
3. Bouchard JF, Lepicier P, Lamontagne D. Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72: 1859-1870, 2003.
4. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425-433, 2004.
5. Carrier EJ, Auchampach JA, Hillard CJ. Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci USA 103: 7895-7900, 2006.
6. Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166: 3-18, 2005.
7. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185, 1980.
8. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258: 1946-1949, 1992.
9. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 93: 217-224, 1971.
10. Giugliano GR, Giugliano RP, Gibson CM, Kuntz RE. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 91: 1055-1059, 2003.
11. 3 adenosine receptor-mediated protection of the ischemic heart. Pharmacological preconditioning: potential new treatment modalities for the ischemic myocardium. Vasc Pharmacol 42: 271-279, 2005.
12. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5: 247-264, 2006.
13. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C. Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55: 619-625, 2002.
14. Kitsis RN, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med 355: 513-515, 2006.
15. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, Maslov LN, Mekhoulam R, Pertwee RG, Stephano GB. Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131: 523-525, 2001.
16. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R, Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97: 9561-9566, 2000.
17. Mechoulam R. Cannabinoids as Therapeutics, edited by Mechoulam R. Basel: Birkhauser Verlag, 2005.
18. Mechoulam R, Hanus L. Cannabidiol: an overview of some chemical and pharmacological aspects. I. Chemical aspects. Chem Phys Lipids 121: 35-43, 2002.
19. Mirit E, Palmon A, Hasin Y, Horowitz M. Heat acclimation induces changes in cardiac mechanical performance: the role of thyroid hormone. Am J Physiol Regul Integr Comp Physiol 276: R550-R558, 1999.
20. Nachlas MM, Friedman MM, Cohen SP. A method for the quantitation of myocardial infarcts and the relation of serum enzyme levels to infarct size. Surgery 55: 700-708, 1964.
21. Nachlas MM, Shnitka TK. Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. Am J Pathol 42: 379-405, 1963.
22. Onaivi ES, Sugiura T, Di Marzo V. Endocannabinoids - The Brain and Body's Marijuana and Beyond. London: Taylor and Francis, 2006.
23. Pepys MB, Hirschfield GM, Tennent GA, Ruth Gallimore J, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJA, Ley SV, Andrew Aquilina J, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 440: 1217-1221, 2006.
24. Pertwee RG. Pharmacological actions of cannabinoids. In: Handbook of Experimental Pharmacology. New York: Springer, 2005, p. 1-51.
25. 2, non-TRPV1 target in the mouse vas deferens. Neuropharmacology 48: 1139-1146, 2005.
26. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65: 812-819, 2005.
27. 2 receptors. Bull Exp Biol Med 131: 251-253, 2001.
28. Ugdyzhekova DS, Krylatov AV, Bernatskaya NA, Maslov LN, Mechoulam R, Pertwee RG. Activation of cannabinoid receptors decreases the area of ischemic myocardial necrosis. Bull Exp Biol Med 133: 125-126, 2002.
29. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol 278: 279-283, 1995.
30. Vivaldi MT, Eyre DR, Kloner RA, Schoen FJ. Effects of methylprednisolone on collagen biosynthesis in healing acute myocardial infarction. Am J Cardiol 60: 424-425, 1987.
31. 1 cannabinoid receptor antagonism promotes remodeling and cannabinoid treatment prevents endothelial dysfunction and hypotension in rats with myocardial infarction. Br J Pharmacol 138: 1251-1258, 2003.
32. 1 receptors. Eur J Pharmacol 423: 203-210, 2001.
33. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39: 143-151, 2006.
34. Xu Z, Mueller RA, Park SS, Boysen PG, Cohen MV, Downey JM. Cardioprotection with adenosine A2 receptor activation at reperfusion. J Cardiovasc Pharmacol 46: 794-802, 2005.
35. + T lymphocytes. Circulation 114: 2056-2064, 2006.
36. 2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111: 2190-2197, 2005.
37. Ytrehus K, Liu Y, Tsuchida A, Miura T, Liu GS, Yang XM, Herbert D, Cohen MV, Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol Heart Circ Physiol 267: H2383-H2390, 1994.
38. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517-1526, 2003.